Module 4: Optimizing outcomes in spasticity treatment
暂无分享,去创建一个
[1] A. Esquenazi,et al. Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity , 2020, Frontiers in Neurology.
[2] D. Dressler,et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy , 2020, Neurology.
[3] H. Hefter,et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy , 2018, Neurology.
[4] K. Fheodoroff,et al. An international survey of patients living with spasticity , 2017, Disability and rehabilitation.
[5] A. Esquenazi,et al. Poster 312 Muscle Selection Patterns for Injection of OnabotulinumtoxinA in Adult Patients with Post‐Stroke Lower‐Limb Spasticity Influence Outcome: Results from a Double‐Blind, Placebo‐Controlled Phase 3 Clinical Trial , 2016, PM & R : the journal of injury, function, and rehabilitation.
[6] David J. Anderson,et al. Best Practices for Intrathecal Baclofen Therapy: Troubleshooting , 2016, Neuromodulation : journal of the International Neuromodulation Society.
[7] J. Jankovic,et al. Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia , 2013, Toxins.
[8] S. Henly,et al. Understanding spasticity from patients' perspectives over time. , 2012, Journal of advanced nursing.
[9] D. Stokic,et al. Effect of concentration and mode of intrathecal baclofen administration on soleus H-reflex in patients with muscle hypertonia , 2012, Clinical Neurophysiology.
[10] Matthew A. Brodsky,et al. Diffusion of Botulinum Toxins , 2012, Tremor and other hyperkinetic movements.
[11] A. Pickett. Consistent Biochemical Data are Essential for Comparability of Botulinum Toxin Type A Products , 2011, Drugs in R&D.
[12] M. Turner. Assessing Syndromes of Catheter Malfunction With SynchroMed Infusion Systems: The Value of Spiral Computed Tomography With Contrast Injection , 2010, PM & R : the journal of injury, function, and rehabilitation.
[13] Kenneth Ngo,et al. Poster 45: Failure to Identify Intrathecal Baclofen Pump/Catheter Problems Can Lead to Unnecessary Healthcare Costs: A Case Report , 2009 .
[14] S. Dodd,et al. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications , 2008, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.
[15] A. Marchetti,et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. , 2000, Clinical therapeutics.
[16] C. Sampaio,et al. DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.
[17] I. Sanders,et al. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis , 1993, Muscle & nerve.
[18] I. Baguley,et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. , 2010, Journal of rehabilitation medicine.
[19] W. Herzog,et al. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. , 2008, Journal of biomechanics.